Parkinson's Disease

Tremors can also result from metabolic alkalosis, a correctable condition where blood pH is excessively alkaline, rather than from neurodegeneration. No currently approved treatment slows or halts neurodegeneration in PD; all approved therapies address symptoms only. Animal studies are presented as suggesting that reducing the harmful target could move disease-related levels toward baseline. Parkinson's disease affects approximately 11.8 million people worldwide as of 2021, with prevalence projected to nearly double to 25.2 million by 2050. PD produces motor symptoms including tremor, rigidity, bradykinesia, gait disturbance, and postural instability, as well as non-motor symptoms such as depression, hallucinations, and cognitive impairment. A Parkinson’s-associated protein is described as dangerous when it changes form or aggregates. The masked face presentation in Parkinson's disease reflects neurological impairment of facial movement, not actual emotional depression. Peripheral metabolic dysfunction, including insulin resistance, dyslipidaemia, and elevated inflammatory cytokines, contributes to neurodegeneration in PD. Motor difficulties in PD patients make subcutaneous self-i…